




 Polytechnic Institute of Coimbra 





Selective Internal Radiation Therapy 
Review of the Standard Operating Procedure for 
Selective Internal Radiation Therapy using SIR-















Polytechnic Institute of Coimbra  
Coimbra Health School 
 




Selective Internal Radiation 
Therapy 
Review of the Standard Operating Procedure for 
Selective Internal Radiation Therapy using SIR-
Spheres microspheres labelled with Yttrium 90 
 
 
Ana Rita Catarino 
 
 





































             










The Master`s degree in Nuclear Sciences Applied to Health contributed greatly to my 
intellectual, professional, and personal enrichment.  
 
This was a long and not always easy stage of my life, during which I met many people with 
different experience, knowledge and background that lead to a significant expansion of my 
knowledge. I would like to leave, in this way, a few words of deep gratitude to them. 
 
I would like to thank the Oxford University Hospitals NHS Foundation Trust, namely the 
Radiopharmacy and Medical Physics Departments for all the support. I also want to thank 
personally Mr. Naseer Khan (Radiopharmacy Manager) for all his support and for 
authorizing the collection of data. 
 
A very special thanks goes to Dr. Viktorie Madhusudan Stisova (Radiopharmacy Deputy 
Manager) that valued my ideas and also supported and helped to supervise this project and 
the preparation of the dissertation -  Thank you Vicki for all your collaboration in this project. 
 
Not less important in this process is the St. Bartholomew`s Hospital, namely the 
Radiopharmacy and Nuclear Medicine Department, which I would like to thank for receiving 
me and integrating me within the team and for all the teaching and training provided. A 
special word goes to Dr. Neil Hartman, for giving me this opportunity and for all his support, 
encouragement and friendship during the project. 
 
I would like to thank Professor Francisco Alves for being the responsible for the great 
experience I went through during the academic degree and Professor Antero Abrunhosa, 
who, although being abroad, accepted to supervise this project and was always able to 
provide the information needed. 
 
To my longtime friends and the ones I met during this amazing experience and I keep in my 






To the most important people in my life: my family. My father, mother, sister and 
grandparents, for their unconditional support, words of affection and encouragement in 
difficult times. Thanks for all the values  passed me throughout life, teaching me not to be 
afraid to go further. Without you it would be impossible to achieve my goals, I hope you feel 

































Aim: Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a 
liver-directed therapy for inoperable primary and secondary liver tumours. The aim of this 
study is to review the Standard Operating Procedure (SOP) used in the Radiopharmacy 
Department of the Oxford University Hospital NHS Foundation Trust to prepare 90Y labelled 
SIR-Spheres microspheres, in order to improve the dispensing procedure for delivering the 
intended patient treatment doses. The specification is: the activity prescribed ±10%. 
Methods: Eleven tests were carried out according to the current SOP. Radioactivity was 
diluted in up to 3 or 5 ml of water for injection and inserted into a V-vial. Following this, the 
used syringes and needles were measured using a Capintec Radionuclide Calibrator to check 
for any remaining activity.  Results: One of the doses dispensed (11th) was below the 
specification. This, is in, turn triggered the review of the SOP. The operator must dilute the 
dose up to 3 ml with water for injection and inject it in the V-vial. According to the new 
procedure, using the same syringe and needle the operator must draw up an additional 1 ml 
of water for injection and inject this volume again into the V-vial. This washes the syringe 
and needle and removes any remaining activity. Conclusions: The reviewed SOP to prepare 
90Y labelled SIR-spheres microspheres has shown to improve the dispensing procedure in 
terms of dose delivered to the patient. The collected data has been accepted and the reviewed 
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Radioactive nuclides have been used for cancer therapy since the 1940’s. Traditionally, the 
therapeutic nuclide used was 131I, but “newer” isotopes with particularly favourable nuclear 
properties have emerged. Of those, 90Y is a very interesting nuclide. It has a higher maximum 
beta energy than 131I (2.27 MeV vs 0.81 MeV) that confers better tissue penetration and a 
shorter half-life (2.67 days vs 8.06 days) that allows it to clear the radioactivity from the 
patient in a timely fashion. (1) 
SIRT, also known as radioembolisation is an innovative therapy that has been developed for 
the treatment of unresectable primary and secondary liver tumours.  There are two types of 
products available in SIRT therapy: the SIR-Spheres and the Theraspheres, both using 90Y-
labelled beads.  
The therapy with SIR-Spheres microspheres labelled with yttrium 90 consists in the delivery 
of extremely small biodegradable resin beads, ranging in size between 20-60µ in diameter 
(Figure 1), directly into the liver tumour via the hepatic artery (Figure 2). Because of their 
small size and weight, they are taken by the blood flow to the small blood vessels 
surrounding the tumour where they lodge with a dose of internal radiation up to forty times 
higher than conventional radiotherapy, while sparing the healthy tissue (Figure 3). The 
microspheres do not distribute uniformly in the liver due to the physiology of hepatic arterial 
flow, the tumour to normal liver ratio of the tissue vascularity and the tumour size. The 
margins of the tumour gets higher density per unit distribution of microspheres than the 
normal liver. The microspheres implanted into the liver are not metabolised or excreted and 
they stay permanently in the liver where their radiation is released in order to destroy the 
tumour cells. (2) 
 
Figure 1 - SIRTEX vial. (3) 








Figure 3 - Microspheres labelled with 90Y being delivered to the tumor. (4) 
 
The treatment of liver tumours with SIR-Spheres microspheres is possible because the liver 
tumours receive their blood supply almost entirely from the hepatic artery whereas the 
normal liver is supplied mainly from the portal vein. This means that infusion of labelled 
microspheres into the arterial system results in delivery of effective doses of radiation to the 
tumour without causing intolerable toxicity to the normal liver. (5) 
Candidates for radioembolization are initially examined by hepatic angiogram to identify 
and map the hepatic arterial system, and at that time, a mixture of albumin particles is 
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delivered via the hepatic artery to simulate microspheres. After that, single-photon emission 
computed tomography gamma imaging is used to detect possible shunting of the albumin 
particles into gastrointestinal or pulmonary vasculature. (6) 
Several studies have already demonstrated the efficacy of this technique in the treatment of 
primary and secondary liver tumours, as a single treatment or associated to chemotherapy. 
Randomised controlled studies in patients with liver metastases from colorectal cancer have 
demonstrated that SIRT using 90Y labelled with microspheres significantly increases the 
tumour response and improves the control of the disease. 
A study of 23 patients with unresectable liver tumours, hepatic metastases or HCC not 
responding to polychemotherapy and/or other local treatment has shown only minor side-
effects with all patients still alive in the end of the study. Three-month follow-up 
investigations were available in 13 of 23 patients, which, so far, were showing a marked 
decrease of  18F-FDG uptake, a drop in the level of tumour markers and unchanged or slightly 
decreasing lesion size (as measured by CT) in 10 of 13 patients. Two patients showed stable 
findings, while another patient showed progressive disease. Long-term follow-up 
investigations were available in 2 of 23 patients, showing hepatic and extrahepatic 
progression 6 and 9 months after SIRT with SIR-Spheres confirming that this treatment is a 
promising local therapeutic approach in patients with unresectable liver tumours which is 
feasible and has an acceptable toxicity profile. (7) 
A study was conducted using SIRT for unresectable HCC with intra-arterial infusion of 90Y 
labelled microspheres. The 71 participating patients did not demonstrate any extrahepatic 
disease. After the treatment, in 19 patients (26.7%) a 50% reduction in tumour volume was 
observed after the first treatment. However, the overall objective response in terms of 
changes in alpha-fetoprotein (tumour marker) level was 89% [PR 67%, CR 22%] among the 
46 patients with raised pre-treatment levels. The study had shown that SIRT using 90Y 
microspheres is effective for selected cases of unresectable HCC and is well tolerated. The 
objective response rate in terms of drop in tumour marker levels is higher than that based on 
reduction in tumour volume shown by CT. The non-tumorous liver appears more tolerant to 
internal radiation than external beam radiation. (8) 
SIRT may convert unresectable tumours to resectable ones. This implies that previously 
inoperable liver tumours are now amenable to potentially curative resection or ablation. This 
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treatment increases time to progression of the tumours, extend overall survival and provide 
palliation of symptoms and can also be used allied to chemotherapy. (9) (10) 
In order to provide this treatment effectively, the cooperation between different departments 
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2. Hospital Radiopharmacy 
 
A Radiopharmacy is a facility for manufacturing and dispensing of radioactive drugs, such 
as radiopharmaceuticals for diagnosis and therapy. It also needs to store radioactive 
materials, inventory records and prescriptions of radioactive substances. The 
Radiopharmacy is usually the collection point for radioactive waste and the unit responsible 
for waste storage and disposal. The unit can also be a centre for clinical investigations using 
radioactive tracers. It may also be a centre for research and for training of students and 
residents in radiology or nuclear medicine. (11) 
The planning of a Radiopharmacy has to take several factors into consideration, namely the 
present and future needs of the department and compliance with all regulatory requirements. 
The concerns regarding facility design should be the safe production of radiopharmaceuticals 
in terms of good manufacturing and radiation protection practices, so the aims of the 
Radiopharmacy design is based on product protection and operator protection. Relatively to 
product protection, it must be protected from environment and operator contaminants as well 
as cross contamination from other products. Regarding operator protection, the operator 
must be protected from the radiation hazards as a consequence of handling radioactive 
materials and the biohazard present when radiolabelling blood components. Also of great 
importance is the protection of the surrounding environment as radioactive and microbial 
contamination must be prevented from escaping or being accidentally spread to other 
equipment, personal or general equipment. (12) 
The two basic functions of a Radiopharmacy are the manipulation of unsealed radioactive 
materials and the preparation of these in a pharmaceutical form suitable for intravenous 
administration. In the United Kingdom the preparation of diagnostic and therapeutic 
radiopharmaceuticals is undertaken under the legislative control of the Medicines Act 1968. 
Commercial organisations must have a full manufacturing license with the MHRA or the 
EMEA, however organisations working with NHS have two options, to be licensed by the 
MHRA with a Manufacturer`s `Special´ License or working under a Section 10 exemption 
of the Medicines Act 1968, where medicinal products are dispensed under the direct 
supervision of a pharmacist. When manufacturing the guidelines provided in Rules and 
Guidance for Pharmaceutical Manufacturers and Distributors (GMP) (MHRA 2007) must 
be followed. (13) (14) 
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Diagnostic or therapeutic radiopharmaceuticals do not normally have any pharmacological 
effect and their administration is not associated with major clinical side effects. Their clinical 
use, however, is associated with a risk deriving from radiation exposure and possible 
contamination during radiopharmaceutical formulation by chemical, biological and 
microbiological impurities. This is particularly important since the majority of 
radiopharmaceuticals are administered intravenously. A thorough QA programme should, 
therefore, being in place and responsibilities clearly assigned.  
Radiopharmaceuticals tend to differ from normal medicines in that they have a relatively 
“short” shelf-life. When manufactured in house, because of their rapid decay, they must be 
prepared shortly before their clinical use and comprehensive QC of the final product is not 
always possible: sterility testing, for instance, cannot be performed before patient 
administration because of time constrains. Safe and effective preparation and use of 
radiopharmaceuticals is, therefore, vital for the protection of the operator and the final user, 
the patient. Radiopharmaceuticals that contain radionuclides with longer half-lives as 90Y 
SIR-Spheres microspheres are normally obtained as market-authorised finished products 




2.1. Radiopharmacy Facility - Cleanroom 
The dispensing of the 90Y SIR-Spheres microspheres is carried out in the Hospital 
Radiopharmacy constituted for cleanroom dedicated for manufacturing and dispensing of 
radiopharmaceuticals. In Oxford University Hospitals NHS Foundation Trust there are two 
different spaces connected with the cleanroom: the preparation room and the packing area. 
The preparation room is the area where the sundries, kits and radiopharmaceuticals used 
during the daily production are stored and is connected with the cleanroom through a 
changing room and one hatch. The packing area is connected with the cleanroom through 
one hatch and in this area the radiopharmaceuticals are not just packed and sent to the 
costumers as well as their radiochemical purity is tested in order to ensure they can be safely 
injected into patients. As part of the Radiopharmacy there is also a store room to keep the 
stock of material, the delivery radioactive store, the radioactive waste store and the reception 
area. 
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The main focus is the cleanroom, essential to carry out the dispensing of the 
radiopharmaceuticals. The cleanroom is a separate, dedicated and secure area. The 
operational area is always kept in good condition, and hygiene must always be ensured. The 
area meet local and national safety codes, including fire safety codes. The space is 
specifically designed and maintained to handle unsealed radionuclides so as to meet the 
required radiation safety standards. All work surfaces are smooth and impermeable, 
permitting easy cleaning and decontamination. Pipe work and cables are encased and 
properly laid to facilitate cleaning and decontamination. The space is sufficient to 
accommodate all essential equipment and accessories such as two isolators and radionuclide 
calibrators with adequate lead shielding around, L-shaped lead shields for handling 
radiopharmaceuticals, and shielded sharps waste storage containers (one for short lived 
radionuclides and the other for long lived radionuclides) and allow for at least two staff 
members to operate simultaneously. There are a sufficient number of long handle forceps, 
tongs, syringe shields, vial shields, shielded syringe carriers for gamma or positron emitting 
radionuclides and suitable shielding devices for handling beta emitting radionuclides. The 
work areas maintain satisfactory lighting, temperature and humidity to ensure the operator 
comfort, optimum equipment performance and expected radiopharmaceutical stability.  
Each isolator, TDS and VPS (where the 90Y SIR-Spheres microspheres are dispensed) 
presents a HEPA-filtered air supply. As the isolators are contained workstations providing 
the necessary environment conditions for aseptically producing and dispensing 
radiopharmaceuticals and radiotherapies such as SIRT they must comply with GMP Grade 
A and is recommended that isolators operating with negative pressure with respect to the 
background environment be used and the environment background is a minimum of GMP 
Grade D. (12) (16) 
In terms of Grade, a cleanroom is defined as a room where the concentration of particles is 
controlled, constructed and operated in a manner that minimises the introduction, generation 
or retention of particles inside the room, and where parameters such as temperature, humidity 
and air pressure are also controlled. There are a number of systems used to classify 
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Maximum permitted number of particles per m3 equal to or 
greater than the tabulated size 
At rest  Operational 
0.5µm 5µm 0.5µm 5µm 
A 3 520 20 3 520 20 
B 3 520 29 352 000 2 900 
C 352 000 2 900 3 520 000 29 000 
D 3 520 000 29 000 Not defined Not defined 
 
 
Regarding the properties of the cleanroom, in terms of air purity, the air is supplied by an air 
conditioning plant through diffusers in the ceiling that insure 20 to 60 total air changes per 
hour to dilute to an acceptable concentration any possible airborne contaminants produced 
in the room. Relatively to the air supply, the air enters into the cleanroom via HEPA filters 
capable of filtering 99.97% of all particles greater than 0.3µm. These filters are placed at the 
point of discharge of air into the room. In terms of room pressurisation, the cleanroom is 
positively pressurised to ensure air does not pass from the adjacent dirty areas, this is 
achieved by extracting slightly less air than the air supplied; to achieve this and to ensure air 
moves from areas of highest cleanliness to less clean in the cleanroom suite, it passes through 
grilles or extract ducts located at low levels in walls and doors. (12) 
 
Table 2 - Recommended limits for microbial contamination. (17) 
(a) these are average values.  
(b) individual settle plates may be exposed for less than 4 hours. 




Recommended limits for microbial contamination (a) 
Air sample 
cfu/m3 
Settle plates  
(diameter 90mm) 
 cfu/4h (b) 
Contact plates  
(diameter 5mm) 
cfu/plate 
Glove Print  
5 fingers 
cfu/glove 
A < 1 < 1 < 1 < 1 
B 10 5 5 5 
C 100 50 25 - 
D 200 100 50 - 
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2.2. Operational Levels 
The procedures performed in the field of a Hospital Radiopharmacy can vary considerably 
in different parts of the world. However, for clarity, these differences can be classified into 
three broad categories: operational levels 1, 2 and 3. Each category can be further subdivided 
to provide essential advice on staff qualifications, training, facilities, equipment, types of 
procedures, record keeping, QA and QC are essential at that level. The operational level 1 
and 2 are subdivided in a and b and the operational level 3 is subdivided in a, b and C. 
The operational level 1a applies to the dispensing of radiopharmaceuticals purchased or 
supplied in their final form from recognized and/or authorised manufacturers or centralized 
radiopharmacies. This includes unit doses or multiple doses of prepared 
radiopharmaceuticals for which no compounding is required. The dispensing of 90Y SIR-
Spheres microspheres should be undertaken under 1b which applies to the dispensing of 
radioiodine and other ready to use radiopharmaceuticals for radionuclide therapy or 
palliation. This includes ready to use injections of strontium and samarium for pain 
palliation. 
Operational level 2a is the preparation of radiopharmaceuticals from prepared and approved 
reagent kits, generators and radionuclides (closed procedure). This is the most common 
activity in nuclear medicine departments, with routine use of a technetium generator and 
reconstitution of pre-sterilized radiopharmaceutical cold kits. The operational level 2b is the 
radiolabelling of autologous blood cells. This includes radiolabelling of red blood cells, 
platelets and white cells commonly used for infection or inflammation imaging. 
The operational level 3a is applicable for  the compounding of radiopharmaceuticals from 
ingredients and radionuclides for diagnostic application (including open procedure); 
modification to existing commercial kits; in-house production of reagent kits from 
ingredients, including freeze dried operation; related research and development. Operational 
level 3b applies to the compounding of radiopharmaceuticals from ingredients and 
radionuclides for therapeutic application (including open procedure) together with related 
research and development. The operational level 3c is the synthesis of PET 
radiopharmaceuticals. This includes the increasingly popular 18F-FDG injections among 
others. The compounding of radiopharmaceuticals produced from unauthorized or long lived 
generators such as 68Ga or 188Re - mostly related research and development - also falls under 
operational level 3c. (15) 
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2.3. Operating personnel and training 
The practice of Radiopharmacy combines the expertise of manufacturing and dispensing 
pharmaceuticals or therapies and the skills needed to handle radioactive substances. To work 
in a Radiopharmacy the qualifications required for personnel should be in accordance with 
local regulations. When, however, these do not cover the qualifications needed for 
Radiopharmacy staff, it is suggested that the preparation and dispensing of 
radiopharmaceuticals is carried out by one of the following professionals: a nuclear 
technologist, medical doctor, pharmacist, chemist, biologist or nurse after completion of a 
basic training programme in radiation physics and instrumentation; mathematics of 
radioactivity use and measurement; radiation protection and regulations; radiation biology; 
radiopharmaceutical chemistry; and the clinical use of radiopharmaceuticals.(15) 
All personnel should also receive practical training (hands on experience) in preparation, QC 
and analytical techniques, transport, laboratory cleaning and maintenance, equipment 
calibration and maintenance, preparation of individual doses and documentation as described 
in detail by the IAEA. Training should include a session on how to comply with aseptic 
procedure as part of GMP that must be in operation throughout the whole process. According 
to the level of operation, individual staff members should receive specific training which are 
described under each specific operational level. Any compounding as described in 
operational level 3 requires a qualified professional with certified training. (15) (16) 
GMP is the minimum standard that manufacturers of medicinal products must meet in their 
production processes with a consistent high quality, to be appropriate to their intended use 




2.4. Standard Operating Procedure 
All the procedures in the Radiopharmacy are described in SOPs. A SOP is a set of detailed 
written instructions that document a routine or repetitive activity followed by an 
organization. The development and use of SOPs are an integral part of a successful quality 
system as it provides individuals with the information to perform a job properly, and 
facilitates consistency in the quality and integrity of a product or end-result. They document 
the way activities are to be performed to facilitate consistent conformance to technical and 
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quality system requirements and to support data quality. They may describe, for example, 
fundamental programmatic actions and technical actions such as analytical processes, and 
processes for maintaining, calibrating, and using equipment. SOPs are intended to be specific 
to the organization or facility whose activities are described and assist that organization to 
maintain their QC and QA processes and ensure compliance with local, national and 
international regulations. (17) 
If not written correctly, SOPs are of limited value. In addition, the best written SOPs will 
fail if they are not followed. Therefore, the use of SOPs need to be reviewed and re-enforced 
by management, preferably the direct supervisor. Current copies of the SOPs also need to be 
readily accessible for reference in the work areas of those individuals actually performing 
the activity, either in hard copy or electronic format, otherwise SOPs serve little purpose. 
The development and use of SOPs minimize variation and promotes quality through 
consistent implementation of a process or procedure within the organization, even if there 
are temporary or permanent personnel changes. SOPs can indicate compliance with 
organizational and governmental requirements and can be used as a part of a personnel 
training program, since they should provide detailed work instructions. It minimizes 
opportunities for miscommunication and can address safety concerns. When historical data 
are being evaluated for current use, SOPs can also be valuable for reconstructing project 
activities when no other references are available. In addition, SOPs are frequently used as 
check lists by inspectors when auditing procedures. Ultimately, the benefits of a valid SOP 
is to reduced work effort, along with improved comparability, credibility, and legal 
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3. Radiation Protection 
 
In order to work safely with radioactive materials, there are radiation protection measures 
that must be taken into account. These measures are described in the ICRP and they are 
applicable not just in the United Kingdom but also in other countries around the world.  
A fundamental principle of ICRP is to keep the activity ALARP.  Radiation dose is received 
by irradiation from an external or internal source and directly absorbed into the body. In 
order to reduce the exposure we need the correct application of the three well-known dose-
saving factors: time, distance and shielding. Time, means that the shorter the exposure to a 
radiation source the less dose is received. Shielding means that all radioactive sources should 
be returned to their container as soon as possible. Bins full of hot waste should be removed 
and placed away from staff members whenever possible. Distance, refers to the intensity and 
hence the absorbed dose from a radioactive source. It varies inversely as the square of the 
distance from the source (the “inverse square law”). So by doubling the distance, the dose 
rate drops to 1/4. The effects of radiation can be even worse at close distances, if for example 
the fingers are touching the external surface of the gamma emitting glass vial the dose may 
be one hundred times higher than that experienced by using tongs of reasonable length. 
Making a 10-fold increase in distance between source and finger means a 100-fold reduction 
in absorbed dose. In terms of shielding, the shield equipment should be adequate to the kind 
of isotope to be handling. (20) (21) 
The electrons from beta emitters, as 90Y, can be completely absorbed by with 1cm of Perspex. 
In comparison, gamma emitter show an exponential absorption with any absorber but this 
absorption depends on the energy of the gamma radiation and the atomic number and density 
of absorber. For low gamma energies the absorption varies as the cube of the atomic number 




3.1. Beta emitters 
Beta emission occurs through one of three processes of radioactive disintegration by which 
some unstable atomic nuclei spontaneously dissipate excess energy and undergo a change of 
one unit of positive charge without any change in mass number. The three processes are 
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electron capture, positron emission and electron emission. β decay was named (1899) by 
Ernest Rutherford when he observed that radioactivity was not a simple phenomenon. He 
called the less penetrating α- rays and the more penetrating β-rays. Most β particles are 
ejected at speeds approaching that of light. (22)  
90Y decays by electron emission, also called negative β decay (symbolized β−decay). This 
process occurs when a nucleus is “neutron rich.” So that means it has a higher N/Z ratio 
compared to a stable nucleus. Thus, it decays by β− particle emission along with an 
antineutrino (ῡ). An antineutrino is an entity almost without mass and zero charge and is 
primarily needed to conserve energy in the decay. In β− decay, a neutron (n) essentially 
decays into a proton (p) and a β− particle according the example: 
                                                             n                p  +  β−  +  ῡ 
The β−  is emitted with variable energy from zero up to the decay energy. The decay or 
transition energy is the difference in energy between the parent and daughter nuclides. The 
antineutrino carries away the difference between the β− particle energy and the decay energy. 
The β− particle decay can be followed by the emission of radiation gamma, if the daughter 
nuclide is in an exited state and the number of gamma rays emitted depends on the excitation 
energy. After β− decay, the atomic number of the daughter nuclide is one more than that of 
the parent nuclide. However, the mass number remains the same for both nuclides. In 
comparison with other forms of radioactivity, such as γ or α-decay, β-decay is a relatively 
slow process. Half-lives for β decay are never shorter than a few milliseconds. (23) 
90Y is a high energy pure β− emitting isotope that decays to stable 90Zr with a physical half-
life of 64.1 h. The emitted particle has a maximum energy of 2.27 MeV and a mean of 
0.93MeV. The mean tissue penetration is 2.5 mm and the maximum is 10 mm. In therapeutic 
use, considering the isotope decay to infinity, 94% of the radiation is delivered in 11 days. 
The average number of particles implanted in the liver is 30 – 60 x 106. (2)  
 
90Y                   90Zr  +  β−  +  ῡ 
90Y (Z= 39, N=51) decays to 90Zr (Z=40, N=50) by emission of a beta particle and an 
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3.2. Controlled and Supervised areas 
The designation of areas is an important part of radiation protection practice and must be 
adequately described in the Local Rules however it is an area which is often mismanaged 
either because of under-designation or over designation.  
The cleanroom is designated as a Controlled Area, this is an area that when following a risk 
assessment indicates to be an area where it is necessary for a person who enters to follow 
special procedures designed to restrict exposure or prevent or limit the probability of a 
radiation accident or if the dose to an employee (aged 18 or over) working in the area is 
likely to exceed any of the values in column 2 of Table 3. Special procedures refer to more 
than ‘generic safety procedures’ which would ordinarily be applied in that area regardless. 
They are procedures specifically designed for the purpose of radiation protection. 
With respect to numerical limits, IRR99 does not go further than the above criteria. The 
ACoP does however include additional requirements for Controlled Area designation which 
are where: 
 the average external dose rate exceeds 7.5µSv/h over a working day. 
 the hands of an employee can enter an area and the 8 hour time averaged dose rate 
in that area is 75µSv/h; 
 there is a significant risk of spreading radioactive contamination outside the 
working area; 
 it is necessary to prevent (or closely supervise) access to the area by employees 
who are not directly connected to the radiation work. 
The need to control access will also influence the decision as to whether an area needs to be 
designated. There are some management arguments for designating a Controlled Area in 
order to restrict access for reasons other than simply radiation protection – perhaps to 
enhance security. However, over designation should be avoided unless the area can meet all 
the requirements, particularly those in IRR99 outlined later. 
In addition, caution should be given to designating on the basis of expected annual dose to 
employees alone. For example, if an area is occupied by an employee for 2000 hours a year 
(40 weeks, 5 days per week), then a continuous ambient dose rate of only 3 µSv/h would be 
enough to require designation on the basis of 6 mSv/year being reached. 
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The additional requirements designated for a Controlled Area are the physical demarcation 
of the area if reasonably practical and the displaying of suitable signs in suitable positions 
indicating the area designated and nature of the sources and risks, for example it is often 
useful to indicate if there is a contamination risk, a radiation risk or both. In the case of 
external radiation hazards it is also important to mention if this arises from radioactive 
sources or from x-rays.  
Where a Controlled Area has been defined, entry is restricted to either classified workers, if 
the worker is likely to receive an effective dose in excess of 6mSv per year or an equivalent 
dose which exceeds 3/10 of any relevant limit; or a person entering under a written system 
of work which specifies how staff should carry out procedures to ensure the dose received 
will not exceed 3/10 of any limit and an assessment of any dose received must be undertaken. 
A written system of work will likely be acceptable where, for example, the employer has 
designated a whole room as “Controlled” but the work requiring designation is only carried 
out in a small part of it. It would also be appropriate where maintenance or service engineers, 
not normally working with ionising radiation, are required to enter the Controlled Area to 
perform their tasks. Adequacy of a system of work can be undertaken by examining 
appropriate personal dose assessments or recording the occupancy time where, for example, 
dose rates are known to be constant or do not exceed a particular level. 
The employer who has designated an area as being Controlled must ensure that any outside 
workers are subject to arrangements for estimating dose. As soon as possible, an estimate of 
the dose received whilst in the Controlled Area must be entered into his/her radiation 
passbook. In most circumstances this should be undertaken on the day that entry is made 
into the area. 
There are some additional matters in terms of Controlled Areas with radioactive materials, 
particularly in an unsealed form. As there is a significant risk of the spread of radioactive 
contamination from the Controlled Area, the employer must make adequate arrangements 
for its prevention such as, maintenance of washing and changing facilities, the prohibition 
of eating, drinking or similar activity and monitoring any person or goods leaving the area 
to avoid contamination trapping.  Workplace monitoring should be undertaken routinely to 
assess the levels of removable contamination and airborne contamination. Airborne 
contamination can be assessed by measuring the level average over any 8 hours period, 
surface contamination may be assessed by wipe techniques on the basis 1/10 of removable 
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contamination has been transferred to the wipe and averaging over 1000 cm2 for floor, walls, 
ceiling and 300 cm2 for other areas. (26) (27) 
A Supervised Area, packing area and waste decay store, is an area which, following a risk 
assessment, has been shown to be an area where is necessary to keep conditions under review 
to determine whether it should be Controlled or Supervised, in which a person is likely to 
receive an effective dose greater than 1mSv per year or an equivalent dose greater than 1/10 
of any relevant dose limit referred in the column 3 of Table 3, or a combination of the two 
situations above mentioned. 
It should be noted that many employers designate an area as Supervised even when 
assessments show that the doses in the third column of the Table 3 are unlikely to be reached. 
This can enhance good radiation protection practices and can be complemented by the 
appointment of a RPS and the adoption of local rules. (26) 
 




3.3. Personal Monitoring 
Staff working in a Radiopharmacy may be designated as classified radiation workers, 
depending on the volume of work they are individually required to do. Staff in an averaged 
sized Radiopharmacy will probably not be designated as classified workers as they will be 
unlikely to exceed 3/10 of any relevant dose limit, however those in a very large 
Radiopharmacy may be classified workers. Additional classified or non-classified staff 
working with radioactive substances or patients should wear at least a personal dosimeter to 
give an estimate of effective dose and a dosimeter on an extremity (finger) to monitor their 
skin extremity dose. (28)  
The body badges used at Oxford University Hospitals NHS Foundation Trust are Luxel Body 
Badges which contains a sheet of radiation-sensitive aluminium oxide sealed in a light and 
Area of Body Controlled Area Supervised Area 
Whole body effective dose 6 mSv 1 mSv 
Lens of eyes 45 mSv 15 mSv 
Skin  150 mSv 50 mSv 
Hands, forearms, feet and ankles 150 mSv 50 mSv 
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moisture proof packet. When the atoms in the aluminium oxide sheet are exposed to 
radiation, electrons are trapped in an excited state until irradiated with a specific wavelength 
of laser light. The released energy of excitation, which is given off as visible light is 
measured to determine radiation dose. The packet contains a series of filters designed so that 
the energy and type of radiation can be determined. In order for the radiation type and energy 
to be determined, the dosimeter must be worn so that the front of the dosimeter faces towards 
the source of radiation. According the manufacturer the Luxel Body Dosimeters are among 
the most sensitive dosimeters available, the minimum detectable dose is 1 mrem for x-rays 
and gamma rays and 10 mrem for energetic beta radiation. 
The ring dosimeter contains a small radiation-sensitive lithium fluoride crystal. When atoms 
in the crystal are exposed to radiation, electrons are trapped in an excited state until the 
crystal is heated to a very high temperature, the released energy of excitation, which is given 
off as visible light, is measured to determine radiation dose, calling this process 
thermoluminescence. The dosimeters that use this principle are often referred to as TLDs. 
TLD dosimeters are slightly less sensitive than Luxel dosimeters; the minimum detectable 
dose for TLD ring dosimeters is 30 mrem for x-rays and gamma rays and 40 mrem for 
energetic beta radiation. Both the body and ring badges do not detect radiation from beta 
emitters with energies less than 250 KeV. 
The Guidelines to use dosimeters must be followed: 
 badges must not be shared or worn by another person, each badge is intended to be 
worn by only the designated person; 
 badges must not be intentionally exposed to radiation, intentional tampering with 
badges is a very serious matter; 
 if it has been discovered that the badges are contaminated, the RSO must be 
promptly notified and replacement badges must be requested; 
 badges must not be worn when receiving a medical x-ray or other medical radiation 
treatment. The badges are intended to document occupational dose, not medical 
dose. (29) (30) 
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3.4. Waste Management 
There is a legal obligation for users of radioactive materials in the United Kingdom to 
comply with the RSA93, unless they are working under an exemption order, which is very 
unlikely to apply to a Hospital Radiopharmacy. This act ensures control over the use of 
radioactive material and its resulting waste. As the waste is potentially harmful, it is 
important to store and dispose it safely. Furthermore, it needs to be taken into account that 
waste is not produced in unnecessary quantities. Thus, control is necessary over the use and 
storage of radioactive materials, as well as to have an efficient waste management system in 
place.  
The EA provides a regulatory system of registration and authorisation for the use, 
accumulation and disposal of radioactive materials. They inspect premises and departments 
whether or not they are fit for purpose and if satisfied, issue the appropriate permits. (31) 
At the Radiopharmacy at Oxford University Hospitals NHS Foundation Trust, short lived 
isotopes, such as 99mTc, which has a half-life of 6 hours, can be disposed once it has decayed 
below background level. Long lived isotopes are disposed according the decay-in-store 
method, which safeguards the operator as well as members of the public from exposing 
unnecessarily from high radiation. Furthermore, it allows precise monitoring of the decay of 
long lived isotopes. The Radiopharmacy maintains a lead shielded long lived sharps bin as 
well as a safe, depending on the level of remaining activity in the vials. The lead shielded 
long lived sharps bin, will only contain vials, which have a remaining activity of below 
20MBq. Anything above this level, needs to be stored into the lead lined safe, due to its 
safety aspects. An electronic and paper spreadsheet system is maintained for both the long 
lived sharps bin as well as the safe, which records the type of isotope, batch number of vial, 
activity (MBq) and the date of storage. The electronic spreadsheet system works under the 
decay calculation formulae, which then automatically calculates and notifies the operator, 
once the long lived isotope is safe for disposal. A waste database exists, which runs along 
the electronic spreadsheet system and calculates for the operator when the isotopes have 
decayed safely and the bin can be disposed.  The database generates also a unique number 
to each long lived isotope bin. When dispensing 90Y SIR-Spheres microspheres, a new 
radioactive bin is used for each dispensing process. According to IAEA recommendations it 
is crucial to record the estimated 10% of the waste from the dispensed patient dose, which 
is usually retained in syringes, needles and Lacto tubing.  
Selective Internal Radiation Therapy 
19 
 
4. Review of SOP to prepare Yttrium 90 labelled with SIR-
Spheres microspheres in the Hospital Radiopharmacy 
 




Y yttrium labelled SIR-spheres microspheres for injection into the hepatic 
artery to produce therapeutic radioembolisation these working instructions must be followed 
and carried out by a competent person. 
 
1. SIR-Spheres microspheres are intended for use on the day of calibration. At the date 
and time of calibration, the activity in the vial matches the activity printed on the 
label (3GBq ±10%). The microspheres may be used for up to 24 hours after 
calibration. Do not use beyond 24 hours of calibration time. 
2. Please note that the dose may be divided into two, one dose for the left lobe of the 
liver and one for the right lobe of the liver. This will be indicated on the prescription. 
3. The SIR-Spheres microspheres should be drawn up in the VPS. NB: This procedure 
MUST be observed and checked by a second competent member of staff 
4. Materials required: 
 Tongs 
 Forceps 
 Alcohol wipes 
 V-vial* 
 Acrylic V-vial holder * 
 2 x 25g needle (orange) ** 
 5ml syringe* 
 5ml syringe shield (Perspex) 
 21g needle 70mm long * 
 Perspex shield 
 Water for injection * 
 50cm Lacto Tubing** 
 0.2µm filter** 
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 Marker pen 
* 2 will be required if the dose is split into 2 parts 
** 3 will be required if the dose is split into 2 parts 
 
5. Invert the lead pot several times before opening. 
6. Set the calibrator to measure the Yttrium-labelled microspheres. 
7. Quickly open the pot and remove the inner vial (containing the microspheres) with 
tongs and determine the total activity using the calibrator. 
 
NOTE: Accurate measurement requires fully suspended microspheres, so it is important 
to make all measurements quickly. 
 
8. Return the inner vial to the lead delivery pot and place it in the shielded work area 
replace the lid on the lead delivery pot. 
9. Prepare the V-vial as follows. Completely remove centre of aluminium crimp seal 
from sterile V-vial with forceps to expose septum. Use the marker pen to put two dots 
on either side of septum (at 180º from each other) trace a line from each dot vertically 
down the side of the vial top.  Swab the septum with an alcohol wipe. 
10. Place sterile V-vial in the dedicated acrylic V-vial holder and screw on lid. This 
provides stability and shielding for the sterile V-vial. Place the V-vial holder near the 
lead pot in the shielded working area. 
11. Connect a 25 g needle to one end of the Lacto Tubing and a 0.2 µm filter to the other 
end. 
12. Insert the 25 g needle through the septum of the V-vial piercing the septum through 
one of the dots, to create a vent; do not push the needle too far down. The V-vial is 
now ready to receive microspheres. 
13. Prepare the syringe for use by placing it in the Perspex syringe shield and attaching 
the long needle (70 mm). 
14. Determine the volume of SIR-Spheres microspheres to be withdrawn from the vial 
to provide the required patient radiation dose. Please note if the volume is less than 
3ml it will be necessary to dilute the SIR-spheres with water for injection. The 
spheres must be diluted in the syringe before they are added to the V-vial.   
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15. Re-suspend the microspheres by inverting the lead pot. 
16. Remove lid from the lead delivery pot to expose microspheres inner vial. 
17. Partially remove centre of aluminium crimp seal from the microspheres vial with 
forceps to expose septum and swab septum with an alcohol wipe held in forceps. Do 
not fully remove crimp seal. 
18. Repeat stage 11 and then pierce the SIR-sphere vial septum ensuring that the needle 
tip is well clear of the SIR-spheres. 
19. Use the shielded 5ml syringe with long needle to puncture the septum of the SIR-
sphere vial. 
20. Re-suspend microspheres with vigorous mixing by quickly drawing up and expelling 
the microspheres in the shielded 5ml syringe at least six times. 
21. Quickly draw up the volume of SIR-Spheres microspheres containing the calculated 
dose into the shielded 5mL syringe. Carefully remove the 21g needle from the inner 
microspheres vial, recap the needle using forceps and set the dose aside. 
22. To check the dose activity of the V-vial contents (patient specific dose), return the 
inner vial to the calibrator to measure the activity that is left. 
23. If additional activity is required, repeat steps 12 to 14 above to obtain the correct 
patient dose. 
24. If the total volume in the shielded syringe is less than 3ml, draw up enough sterile 
water for injection to make up to a total volume between 3 and 5ml. The water must 
be added whilst the spheres are in the syringe. 
25. Insert the lubricated 21g hypodermic needle into swabbed septum of sterile V-vial 
through the second dot opposite the venting needle and deliver the microspheres from 
the shielded syringe into the V-vial ensuring the spacing between any punctured holes 
in the V-vial is at least 2mm apart and careful not to scrape the V-vial’s sidewalls. 
Note: This step should be done ONCE only. 
26. Remove the vent needle from the V-vial; use the marker pen to clearly write the 
activity and if the dose is split write L for left lobe dose and R for the right lobe dose. 
Ensure lid of the V-vial holder is secure and the plug is in place. 
27. For split doses repeat steps 9 onwards for the second dose. 
28. Remove the vent needle from the shipping vial and replace the lid of the lead delivery 
pot. 
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29. Remove the V-vial and lead pot from the isolator. 
30. Complete the form for  90Y labelled SIR-spheres microspheres 
31. Expiry time for labelled 90Y SIR-Spheres is 24 hours post the calibration time. (32) 
 




4.2. Material and Methods 
After dispensing each SIRT dose prescribed according SPC and SOP, the residue in the 
syringes and needles used to dispense are measured. 
 
1. The 5ml syringe with the needle is removed from the beta syringe shield and 
measured in the Capintec Radionuclide Calibrator - CRC®-15R (SN 510215).  
2. The syringe and needle are placed in the Acrylic (clear) liner PVC using the 
calibration setting 27*10 for measurements of the isotope 90Y in 5 ml syringes. 
3. The radioactivity (MBq) of each syringe and needle measurement is recorded once 
the readings on the calibrator have settled down. 
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4. The residue in the syringe and needle is subtracted from the activity dispensed. The 
activity dispensed is determined by the subtraction of the final activity measured in 
the 90Y inner vial (after dispensing) from the initial activity measured in the 90Y inner 
vial (before dispensing). 
5. The subtraction of the activity in the syringe and needle from the activity dispensed 




























The collection of data resulted initially from the interest of verifying the level of precision 
of radioactivity effectively deliver to the patients.  
The information collected revealed to be important when the patient`s doses started to be 
measured not just in Radiopharmacy but also by the Medical Physics before doses were sent 
for injection. The measurements taken have shown some discrepancies, which needed to be 
further investigated. 
The SIR-Spheres microspheres are labelled with 90Y suspended in an aqueous solution. The 
dense viscosity of microspheres is contributing for the loss of activity when using the 
subtraction method described in the SPC and SOP. 
In order to understand the following tables it is important to note that the activity delivered 
to the patients is the activity effectively dispensed. This activity is obtained by the subtraction 
of the residue in the inner vial and the residue in the syringes and needles from the initial 
activity in the inner vial according the following formulae: 
 
 
Activity Effectively Dispensed = Activity Delivered to the patient 
Activity Effectively Dispensed = 
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The results of the measurements during the dispensing procedure, following SOP NM-L3-
155 are demonstrated in the following tables and charts: 
 








































1 1500 ± 10% 3810 30% 450 19.40 55.1 2320 1490 1434.90 4.34 
70% 1040 35.70 
2 1000 ± 10% 3640 30% 300 25.80 68.6 2600 1040 971.40 2.86 
70% 700 42.80 
3 1500 ± 10% 3600 100% 1630 45.20 45.2 1970 1630 1584.80 5.65 
4 2100 ± 10% 3870 20% 450 48.50 168.5 1606 2264 2095.50 0.21 




1100 ± 10% 
 
3590 









40% 470 14.76 
40% 400 6.68 
6  
1200 ± 10% 
 
3590 







41.67% 520 18.42 
41.67% 510 17.20 
7 2000 ± 10% 2000 100% 2023 44.30 44.3 1647 2023 1978.70 1.06 
8 
 
900 ± 10% 3800 30% 270 12.99 44.39 2920 880 835.61 7.15 
70% 610 31.40 
9 800 ± 10% 3660 100% 860 64.70 64.7 2800 860 795.3 0.59 
10 1800 ± 10% 3700 30% 540 32.80 43.8 1938 1762 1718.2 4.54 
70% 1260 11.00 
11 2100 ± 10% 3750 100% 1940 121 121 1810 1940 1819 13.38 
Average Error (% ± SD) 4.25 ± 3.76 
Selective Internal Radiation Therapy 
26 
 
 Figure 5 - Bar chart demonstrating the relationship between activity prescribed and activity 





The results of the measurements during the dispensing procedure after changes in the SOP 
NM-L3-155 are revealed in the following tables and charts: 
 
Table 5 - Measurements of the residues in the syringe and needle when dispensing SIRT after the 



































12 1500 ±10% 50 3760 27 46 2180 1580 1534 2.27 
50 19 
13 1400 ±10% 30 3730 50 101.6 2220 1510 1408.4 0.6 
70 51.6 
14 900 ±10% 30 3570 22.8 44.9 2800 950 905.1 0.57 
70 22.1 















17 1300 75 3740 14 28 2400 1340 1312 0.92 
25 14 
































Figure 6 - Bar chart demonstrating the relation between activity prescribed and activity effectively 


















































At Oxford University Hospitals NHS Foundation Trust around 100 patients are treated with 
SIR-Spheres microspheres per year. In previous studies I observed that after the dispensing 
procedure large quantities of 90Y labelled SIR-Spheres microspheres have been found in the 
syringes and needles. The department of Medical Physics also confirmed that one of the 
doses dispensed were less than the prescribed activity (<10%). It is crucial for the effective 
treatment of unresectable primary or secondary liver tumours to deliver sufficient and 
accurate amount of microspheres into the hepatic artery. Despite drawing up 90Y labelled 
SIR-Spheres microspheres according to SOP NM-L3-155 a large amount of microspheres 
have been lost in syringes and needles, which have been used to manipulate the dose.  
These findings were confirmed in a series of 11 patients who have undergone this treatment 
and sufficient data was collected to realise that immediate changes in the SOP were required. 
The Radiopharmacy department receives the prescription for a 90Y labelled SIR-Spheres 
microspheres study on the day of the procedure.  The prescription will state the required total 
activity but will also direct (if applicable) the operator to split the activity (‘required splits’), 
which refers to the percentage of dose to be drawn up for each liver lobe.  According to SOP 
NM-L3-155 and manufacturers guidelines, the required  activity of 90Y labelled SIR-Spheres 
microspheres will be drawn up in a 5ml syringe and made up to a final volume between 3ml 
and 5 ml. Locally was set by Radiopharmacy and Medical Physics Experts that the 
radioactivity to be delivered to the patients must be ±10% of the prescribed dose. 
Table 4 shows the eleven SIRT dispensing procedures evaluated and the activity effectively 
delivered to the patients. Procedures were carried out according to SOP NM-L3-155. The 
bar chart in Figure 5 indicates the acceptable ±10% dose activity interval with error bars. In 
nine dispensing procedures (SIRT number: 1, 2, 4, 5, 6, 7, 8, 9, 10) the effective activity 
dispensed and delivered to the patient was below the prescribed activity but within the ±10% 
range. On the other hand, in SIRT number 3, the activity was above the prescribed dose but 
also within the ±10% dose range. In contrast, in SIRT number 11 the delivered activity was 
13.38% lower than the prescribed activity and therefore, outside the ±10% dose range.  
The poor results can be explained due to the high viscosity of the 90Y labelled SIR-Spheres 
microspheres, which are difficult to inject in a sufficient and accurate amount into the V-vial 
containing the patient`s dose.   
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The inaccuracy of the dose delivered to the patients can interfere with the efficiency of the 
treatment. Therefore, it was suggested that in order to dispense the prescribed activity 
accurately and to improve the radiation safety of the operator SOP NM-L3-155 needed to be 
amended.   The “SOP to prepare Yttrium 90 labelled SIR-spheres microspheres” stated that 
the microspheres need to be drawn up in one session with sterile water for injection to a final 
volume between 3 and 5 ml. Retrospectively looking at the data, a large amount of 
microspheres have been lost in the syringes and needles. In order to obtain the remaining 
90Y labelled SIR-Spheres microspheres, the operator must draw up initially the required 
radioactivity with sterile water for injection up to a total volume of 3 ml and inject the 
volume into the V-vial. Following this using the same syringe and needle, the operator must 
wash with sterile water for injection up to a total volume of 1ml and inject the residual 
microspheres into the V-vial.  
After introducing the reviewed SOP, another 6 procedures were carried out and results are 
considered very promising (Table 5 and Figure 6). The data demonstrates that the new 
procedure improved the dose effectively dispensed. In SIRT number 12, 13, 14, 16 and 17 
the activity effectively dispensed is slightly higher than the activity prescribed and in 
procedure 15, is slightly lower. However, it is now always within the range of ±10%.  
The improvements of the reviewed SOP can be justified as well by the percentage of average 
error ± SD of the activity effectively dispensed and delivered to the patients. Before 
implementing any changes in the SOP NM-L3-155 the average error was 4.25 ± 3.76. After 
implementing the reviewed SOP we have got an average error of 1.05 ± 0.63. To conclude, 
the results prior amending the SOP has shown a greater average error than the amended SOP. 
In comparison the reviewed SOP has shown a minor average error shifting the standard 
deviation towards the average, which proves that a change in SOP has led to more reliable 











The changes made in the SOP to prepare 90Y labelled SIR-spheres microspheres (Annex I) 
has shown to improve the dispensing procedure in terms of the dose effectively dispensed 
and delivered to the patient. Furthermore, the new procedure also helps in terms of radiation 
protection, as no more measurements are needed to insure that the correct activity has been 
dispensed.  
The second flush of the V-vial with water for injection allows the operators to wash and 
remove the residues of microspheres labelled with 90Y from the syringe and needle into the 
V-vial, increasing the dose in the V-vial.  
The reviewed SOP permits the operators to be confident about the activity effectively 
delivered to the patient as it provides a significant reduction of the dispensing error.  
It is important to mention that the changes in the SOP, also help the Operators involved in 
the process (dispensing and calculations) to predict the exact dose that will be dispensed for 
each split based on previous results and, therefore, make any necessary adjustments as 
needed. This process associated to the changes in the SOP will give a high degree of certainty 
regarding the efficiency of the dispensed procedure and the dose delivered to the patient.  
The data collected was approved and used as reference by the Radiopharmacy department 
at Oxford University Hospitals NHS Foundation Trust and has been used since then as well 
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9.  Annex I 
 
The described method to dispense 90Y labelled with SIR-Spheres microspheres must be used 
in addition to SOP NM-L3-155 and was implemented from 26/08/2015. 
- Once the V-vial is assembled into the V-vial holder, with lacto tubing ready for 
ventilation and syringes are in the syringe shields: 
 measure the activity of the inner vial using the “P6 vial calibration factor” 
(calibration factor set at Oxford University Hospitals); 
 through the calculations done, draw up the required volume; 
 verify the dose drawn up by measuring of residual activity in the inner vial 
using the  “P6 vial calibration factor”; 
 adjust the dose if necessary; 
 with the syringe and needle containing the drawn up dose, draw up sterile 
water for injection up to a total volume of 3ml and inject the volume in the 
V-vial; 
 with the same syringe and needle draw up sterile water for injection up to a 
total volume of 1ml to remove any residual activity from the syringe and 
needle and inject the volume in the V-vial. 
 
 
 
 
 
 
